Loading…
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study
Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. Patients with metastatic or recur...
Saved in:
| Published in: | Investigational new drugs 2004-01, Vol.22 (1), p.91-97 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013 |
| container_end_page | 97 |
| container_issue | 1 |
| container_start_page | 91 |
| container_title | Investigational new drugs |
| container_volume | 22 |
| creator | Urba, Susan G Chansky, Kari VanVeldhuizen, Peter J Pluenneke, Robert E Benedetti, Jacqueline K Macdonald, John S Abbruzzese, James L |
| description | Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer.
Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival.
Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months.
This regimen is tolerable palliative option for patients with metastatic esophageal cancer. |
| doi_str_mv | 10.1023/B:DRUG.0000006179.20974.af |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_216496509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>530764971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013</originalsourceid><addsrcrecordid>eNpFkMlOwzAQhi0EgrK8ArJ6T_GS2Lg3WiAgVarEcrYcx2lTJXGwHVXl6XEXibnMaOaf7QNgjNEEI0IfZtPnj-98gg7GMBcTggRPJ6o6AyOccZoglrJzMEKY8YQJwa_AtfebqKZRdwmucMoRT4UYgd_ctLoOqqg7A1VXQl37vlGh7mBlHexjZLrg4bYOa9iaoHyIKQ1jzRk9OBer0Hjbr9XKqAZq5XTd2VZNoYKfdgjrrfEBLjttG7vawdzZoYefYSh3t-CiUo03dyd_A75fX77mb8limb_PnxaJpiINCckM4YgWXFCDES5TygnSWfVINXlMiSiUooxpgniGOSkzRggq6P49XnKEML0B4-Pc3tmfIV4jN3ZwXVwpCWapYBkSUTQ9irSz3jtTyd7VrXI7iZHcU5czuacu_6nLA3Wpqth8f9owFK0p_1tPmOkfB7J_eQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216496509</pqid></control><display><type>article</type><title>Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study</title><source>ABI/INFORM global</source><source>Springer Nature</source><creator>Urba, Susan G ; Chansky, Kari ; VanVeldhuizen, Peter J ; Pluenneke, Robert E ; Benedetti, Jacqueline K ; Macdonald, John S ; Abbruzzese, James L</creator><creatorcontrib>Urba, Susan G ; Chansky, Kari ; VanVeldhuizen, Peter J ; Pluenneke, Robert E ; Benedetti, Jacqueline K ; Macdonald, John S ; Abbruzzese, James L ; Southwest Oncology Group Study</creatorcontrib><description>Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer.
Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival.
Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months.
This regimen is tolerable palliative option for patients with metastatic esophageal cancer.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1023/B:DRUG.0000006179.20974.af</identifier><identifier>PMID: 14707499</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer therapies ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - secondary ; Chemotherapy ; Cisplatin - administration & dosage ; Creatinine ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease ; Esophageal cancer ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Female ; Granulocytes ; Humans ; Kinases ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Neoplasm Recurrence, Local ; Oncology ; Patients ; Radiation ; Response rates ; Survival Rate ; Toxicity</subject><ispartof>Investigational new drugs, 2004-01, Vol.22 (1), p.91-97</ispartof><rights>Copyright Kluwer Academic Publishers Jan 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013</citedby><cites>FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/216496509/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/216496509?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,11688,27924,27925,36060,44363,74895</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14707499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Urba, Susan G</creatorcontrib><creatorcontrib>Chansky, Kari</creatorcontrib><creatorcontrib>VanVeldhuizen, Peter J</creatorcontrib><creatorcontrib>Pluenneke, Robert E</creatorcontrib><creatorcontrib>Benedetti, Jacqueline K</creatorcontrib><creatorcontrib>Macdonald, John S</creatorcontrib><creatorcontrib>Abbruzzese, James L</creatorcontrib><creatorcontrib>Southwest Oncology Group Study</creatorcontrib><title>Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer.
Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival.
Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months.
This regimen is tolerable palliative option for patients with metastatic esophageal cancer.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Creatinine</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Female</subject><subject>Granulocytes</subject><subject>Humans</subject><subject>Kinases</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Oncology</subject><subject>Patients</subject><subject>Radiation</subject><subject>Response rates</subject><subject>Survival Rate</subject><subject>Toxicity</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><recordid>eNpFkMlOwzAQhi0EgrK8ArJ6T_GS2Lg3WiAgVarEcrYcx2lTJXGwHVXl6XEXibnMaOaf7QNgjNEEI0IfZtPnj-98gg7GMBcTggRPJ6o6AyOccZoglrJzMEKY8YQJwa_AtfebqKZRdwmucMoRT4UYgd_ctLoOqqg7A1VXQl37vlGh7mBlHexjZLrg4bYOa9iaoHyIKQ1jzRk9OBer0Hjbr9XKqAZq5XTd2VZNoYKfdgjrrfEBLjttG7vawdzZoYefYSh3t-CiUo03dyd_A75fX77mb8limb_PnxaJpiINCckM4YgWXFCDES5TygnSWfVINXlMiSiUooxpgniGOSkzRggq6P49XnKEML0B4-Pc3tmfIV4jN3ZwXVwpCWapYBkSUTQ9irSz3jtTyd7VrXI7iZHcU5czuacu_6nLA3Wpqth8f9owFK0p_1tPmOkfB7J_eQ</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Urba, Susan G</creator><creator>Chansky, Kari</creator><creator>VanVeldhuizen, Peter J</creator><creator>Pluenneke, Robert E</creator><creator>Benedetti, Jacqueline K</creator><creator>Macdonald, John S</creator><creator>Abbruzzese, James L</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>200401</creationdate><title>Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study</title><author>Urba, Susan G ; Chansky, Kari ; VanVeldhuizen, Peter J ; Pluenneke, Robert E ; Benedetti, Jacqueline K ; Macdonald, John S ; Abbruzzese, James L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Creatinine</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Female</topic><topic>Granulocytes</topic><topic>Humans</topic><topic>Kinases</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Oncology</topic><topic>Patients</topic><topic>Radiation</topic><topic>Response rates</topic><topic>Survival Rate</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Urba, Susan G</creatorcontrib><creatorcontrib>Chansky, Kari</creatorcontrib><creatorcontrib>VanVeldhuizen, Peter J</creatorcontrib><creatorcontrib>Pluenneke, Robert E</creatorcontrib><creatorcontrib>Benedetti, Jacqueline K</creatorcontrib><creatorcontrib>Macdonald, John S</creatorcontrib><creatorcontrib>Abbruzzese, James L</creatorcontrib><creatorcontrib>Southwest Oncology Group Study</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM global</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Urba, Susan G</au><au>Chansky, Kari</au><au>VanVeldhuizen, Peter J</au><au>Pluenneke, Robert E</au><au>Benedetti, Jacqueline K</au><au>Macdonald, John S</au><au>Abbruzzese, James L</au><aucorp>Southwest Oncology Group Study</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>2004-01</date><risdate>2004</risdate><volume>22</volume><issue>1</issue><spage>91</spage><epage>97</epage><pages>91-97</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer.
Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival.
Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months.
This regimen is tolerable palliative option for patients with metastatic esophageal cancer.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>14707499</pmid><doi>10.1023/B:DRUG.0000006179.20974.af</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6997 |
| ispartof | Investigational new drugs, 2004-01, Vol.22 (1), p.91-97 |
| issn | 0167-6997 1573-0646 |
| language | eng |
| recordid | cdi_proquest_journals_216496509 |
| source | ABI/INFORM global; Springer Nature |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - secondary Chemotherapy Cisplatin - administration & dosage Creatinine Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease Esophageal cancer Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Female Granulocytes Humans Kinases Male Medical prognosis Metastasis Middle Aged Neoplasm Recurrence, Local Oncology Patients Radiation Response rates Survival Rate Toxicity |
| title | Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A33%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gemcitabine%20and%20cisplatin%20for%20patients%20with%20metastatic%20or%20recurrent%20esophageal%20carcinoma:%20a%20Southwest%20Oncology%20Group%20Study&rft.jtitle=Investigational%20new%20drugs&rft.au=Urba,%20Susan%20G&rft.aucorp=Southwest%20Oncology%20Group%20Study&rft.date=2004-01&rft.volume=22&rft.issue=1&rft.spage=91&rft.epage=97&rft.pages=91-97&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1023/B:DRUG.0000006179.20974.af&rft_dat=%3Cproquest_cross%3E530764971%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c394t-25e2703b793e101d43720c5f83c28429baa366c2075172d56220b307497d70013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=216496509&rft_id=info:pmid/14707499&rfr_iscdi=true |